The report highlights PharmaBlock's first Environmental, Social and Governance (ESG) report, which includes details on the company's management strategies, practices, and performance in environmental, social, and corporate governance areas. The report covers the period from January 1, 2022 to December 31, 2022 and is consistent with the Company's annual report. It details specific highlights from the year, including the company's investment in R&D, which reached RMB 168.32 million, with an increase of 47.62% year-over-year, and the R&D expense ratio remained at an industry-high level.
Issuing Company Pharmablock Sciences
Report Type Sustainability Report
Report Language EN
Report Filesize 25.5 MB
No. of Pages 54 pages
Reporting periodJanuary 1st, 2022 to December 31st, 2022
Report Edition1
Assurance Provider Unknown
Reporting Standards Shenzhen Stock Exchange Guidelines 2; ESG Expert Committee of...
Materiality Assessmenttrue